Stockreport

Afamelanotide in fair-skinned Parkinson’s patients

CLINUVEL PHARMS LTD S/ADR  (CLVLY) 
NASDAQ:AMEX Investor Relations: clinuvel.com/investors
PDF MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkin [Read more]